The components data of fuzheng huayu extracts, cordyceps sinensis mycelia polysaccharide, gypenosides and amygdalin

Liu, Wei; Li, Zhixiong; Sun, Zhaolin; Xu, Yongbin; Wang, Shunchun; Hu, Yiyang; Peng, Jinghua

doi:10.1016/j.dib.2019.104087

Cited by 4 publications

(2 citation statements)

References 9 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fuzheng Huayu (FZHY, traditional Chinese medicine) is a blend of six herbs [ 85 ]. The formulation has been approved for the treatment of liver fibrosis by the China Food and Drug Administration [ 86 ].…”

Section: Clinical Trials Of Therapies For Post-covid Lung Fibrosismentioning

confidence: 99%

Lung Fibrosis after COVID-19: Treatment Prospects

et al. 2021

View full text Add to dashboard Cite

At the end of 2019, a highly contagious infection began its ominous conquest of the world. It was soon discovered that the disease was caused by a novel coronavirus designated as SARS-CoV-2, and the disease was thus abbreviated to COVID-19 (COVID). The global medical community has directed its efforts not only to find effective therapies against the deadly pathogen but also to combat the concomitant complications. Two of the most common respiratory manifestations of COVID are a significant reduction in the diffusing capacity of the lungs (DLCO) and the associated pulmonary interstitial damage. One year after moderate COVID, the incidence rate of impaired DLCO and persistent lung damage still exceeds 30%, and one-third of the patients have severe DLCO impairment and fibrotic lung damage. The persistent respiratory complications may cause substantial population morbidity, long-term disability, and even death due to the lung fibrosis progression. The incidence of COVID-induced pulmonary fibrosis caused by COVID can be estimated based on a 15-year observational study of lung pathology after SARS. Most SARS patients with fibrotic lung damage recovered within the first year and then remained healthy; however, in 20% of the cases, significant fibrosis progression was found in 5–10 years. Based on these data, the incidence rate of post-COVID lung fibrosis can be estimated at 2–6% after moderate illness. What is worse, there are reasons to believe that fibrosis may become one of the major long-term complications of COVID, even in asymptomatic individuals. Currently, despite the best efforts of the global medical community, there are no treatments for COVID-induced pulmonary fibrosis. In this review, we analyze the latest data from ongoing clinical trials aimed at treating post-COVID lung fibrosis and analyze the rationale for the current drug candidates. We discuss the use of antifibrotic therapy for idiopathic pulmonary fibrosis, the IN01 vaccine, glucocorticosteroids as well as the stromal vascular fraction for the treatment and rehabilitation of patients with COVID-associated pulmonary damage.

show abstract

Section: Clinical Trials Of Therapies For Post-covid Lung Fibrosismentioning

confidence: 99%

Lung Fibrosis after COVID-19: Treatment Prospects

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Schisandra chinensis is one of the crucial components in the Chinese prescription, Fuzheng Huayu Recipe, to treat liver diseases mainly hepatitis B induced fibrosis (Liu et al, 2019a). Deoxyschizandrin was identified as a compound possessing the function to change the cytochrome P450 enzyme activity during hepatic fibrogenesis (Liu et al, 2019b). It was reported that the metabolism of deoxyschizandrin involved the P450 isoforms CYP3A4 and CYP3A5 (Yang et al, 2015).…”

Section: Other Compounds From Herbs or Plantsmentioning

confidence: 99%

Targeting Hepatic Stellate Cells for the Treatment of Liver Fibrosis by Natural Products: Is It the Dawning of a New Era?

Wang

Tan

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Liver fibrosis is a progressive liver damage condition that is worth studying widely. It is important to target and alleviate the disease at an early stage before turning into later cirrhosis or liver cancer. There are currently no direct medicines targeting the attenuation or reversal of liver fibrosis, and so there is an urgent need to look into this area. Traditional Chinese Medicine has a long history in using herbal medicines to treat liver diseases including fibrosis. It is time to integrate the ancient wisdom with modern science and technology to look for the best solution to the disease. In this review, the principal concept of the pathology of liver fibrosis will be described, and then some of the single compounds isolated from herbal medicines, including salvianolic acids, oxymatrine, curcumin, tetrandrine, etc. will be discussed from their effects to the molecular mechanism behind. Molecular targets of the compounds are analyzed by network pharmacology approach, and TGFb/SMAD was identified as the most common pathway. This review serves to summarize the current findings of herbal medicines combining with modern medicines in the area of fibrosis. It hopefully provides insights in further pharmaceutical research directions.

show abstract